Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Liabilities (2016 - 2025)

Iovance Biotherapeutics has reported Total Liabilities over the past 13 years, most recently at $214.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $214.6 million for Q4 2025, up 7.28% from a year ago — trailing twelve months through Dec 2025 was $214.6 million (up 7.28% YoY), and the annual figure for FY2025 was $214.6 million, up 7.28%.
  • Total Liabilities for Q4 2025 was $214.6 million at Iovance Biotherapeutics, up from $202.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for IOVA hit a ceiling of $214.6 million in Q4 2025 and a floor of -$773.5 million in Q3 2024.
  • Median Total Liabilities over the past 3 years was $192.8 million (2023), compared with a mean of $32.0 million.
  • Biggest five-year swings in Total Liabilities: plummeted 533.78% in 2024 and later surged 127.19% in 2025.
  • Iovance Biotherapeutics' Total Liabilities stood at $195.7 million in 2023, then rose by 2.19% to $200.0 million in 2024, then increased by 7.28% to $214.6 million in 2025.
  • The last three reported values for Total Liabilities were $214.6 million (Q4 2025), $202.7 million (Q3 2025), and $208.9 million (Q2 2025) per Business Quant data.